Canada’s decision to legalize the recreational use of cannabis has allowed the rise of an emerging investment market. The cannabis public sector has become one of the most followed industries for investors. 

As such, the Investing News Network brings investors a collection of stories on the critical transition and its impact on the public markets.

Cannabis stocks took a dive on Wednesday (October 17), the same day for official legalization of adult-use marijuana in Canada.

Canadian producers such as Canopy Growth (NYSE:CGC,TSX:WEED), HEXO (TSX:HEXO), and Aurora Cannabis (TSX:ACB) all noticed declines in value on Wednesday. Respectively, each stock declined 4.38, 5.95 and 2.93 percent in value.

The Horizons Marijuana Life Science Index ETF (TSX:HMMJ), started the day with a drop and reached a day-low of C$22.79.

The index, which holds nearly 40 pot stocks, picked up the rest of the day to finish with a 2.10 percent drop and a closing price of C$24.30.

The Evolve Marijuana ETF (TSX:SEED) also dropped in value on Wednesday, seeing a 1.98 percent loss and a closing price of C$1.98. This index counts with 20 holdings in the cannabis space.

An alternative ETF from Horizons, the Horizons Emerging Marijuana Growers Index ETF (AQN:HMJR), which exclusively holds cannabis companies with a market capitalization between C$50 million and C$500 million, declined 2.33 percent to a price of C$9.21.

A couple of outliers in Wednesday’s drop among leading cannabis companies were Aphria (TSX:APH) and CannTrust Holdings (TSX:TRST) which, despite the losses around the market, actually saw increases throughout the day.

Aphria closed the trading session with a 3.80 gain and a price of C$19.40, while CannTrust took a marginal 1.26 percent gain to finish with a closing price of C$13.67.

“The Cannabis Act, which comes into effect today, cements Canada’s global leadership in this rapidly expanding industry,” Vic Neufeld, CEO of Aphria, said in a statement. This is an historic moment as we march into the future of cannabis.”

Performance of US stocks from Canadian companies

The move from Canadian cannabis companies launching stocks on US premier exchanges, such as the New York Stock Exchange (NYSE) or NASDAQ, has attracted investors below the border to gain exposure into the space.

Tilray (NASDAQ:TLRY), which garnered the attention of the market with the company reaching a market cap of over US$10 billion, joined in with the overall sector and faced a 6.40 percent drop to its stock to US$148.25 per share.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

Shares of Cronos Group (NASDAQ:CRON,TSX:CRON) fell 4.38 percent, representing a loss of US$2.32. The stock closed the trading session with a price per share of US$50.69.

Canopy’s NYSE stock, similar to its Toronto stock, dropped in value as the investor sentiment gravitated towards sales on Wednesday.

The stock opened the day with a US$2.76 decline in value. During the trading session, the stock went down 4.38 percent and held a value of US$50.69 during after hours trading.

Investor takeaway

Wednesday’s losses had been predicted, albeit not a total crash, but a potential decline for cannabis stocks instead of a catalyst leading to gains in the public market.

Everett Knight, portfolio manager with Matco Financial, told the Investing News Network (INN) he expected to see a lot of retail money selling.

Knight said the cannabis play remains an early one and expects the next few quarters to deliver more answers on the entire sector.

“Cannabis investors will have to become more sophisticated and not paint the whole industry with same brush to make better returns.”

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

Investing in cannabis? Read what experts have to say about cannabis and the US Election!

PharmaTher Inc., a wholly-owned subsidiary of Newscope Capital Corporation (“PharmaTher”) (CSE: PHRM) and a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to provide a corporate update on its psychedelic pharmaceuticals program. Since its inception, the Company has built a unique product pipeline for novel uses of ketamine, psilocybin and undisclosed psychedelics. PharmaTher is positioning itself to partner its psilocybin program and panaceAI™, and focus on advancing its novel ketamine product pipeline in Parkinson’s disease, depression and pain via the U.S. Food and Drug Administration (“FDA”) regulatory pathway.

“We have made tremendous progress over the last several months that saw our product pipeline evolve to focus on the massive opportunity and potential of ketamine, an FDA approved drug with a known safety profile, to treat significant unmet medical needs for Parkinson’s disease, depression and pain,” said Fabio Chianelli, CEO of PharmaTher. “With our focus on ketamine through repurposing, combining it with an FDA approved drug and delivering it with our novel microneedle delivery system, we are now positioned to expedite our clinical development objectives by taking advantage of the FDA’s 505(b)(2) regulatory pathway and commercializing disruptive ketamine treatments for mental health and pain disorders.”

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB)(TSX: ACB), and Canopy Growth Corporation (NASDAQ: CGC) (TSX: WEED).

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

Chemesis International Inc. (the “Company”) (CSE:CSI)(OTCQB:CADMF)(FRA:CWAA

The Company announces that its (former) subsidiary, Natural Ventures PR, LLC (“NVPR”), has sold all of its cannabis assets, and assigned all related liabilities, licenses and permits, to Puerto Rico Industrial Commercial Holdings Biotech Corp. (“PRICH”) in exchange for immediate net cash proceeds to the Company, in respect of its 80% interest in NVRP, of US$450,000. The Company notes that, in connection with, and as a condition to, this transaction, it will cease to be a shareholder of NVPR.

Keep reading... Show less

Progressive Planet Solutions Inc. (TSXV: PLAN) (“PLAN” or “Progressive Planet”), an emerging leader in reducing the carbon footprint of cement products using natural pozzolans, is pleased to announce it has sold and optioned a combined total of 10 million of its 10.5 million shares of Snow Lake Resources.

The sale and option agreements were made with two arms-length purchasers. The first sale was for 1,700,000 shares at $0.04 per share for a total of $68,000 and includes an option granted by PLAN entitling the same party to purchase an additional 4,966,666 shares at $0.04 per share until May 11, 2021 . The second sale was for 1,250,000 shares at $0.04 per share for a total of $50,000 and includes an option granted by PLAN to such party to purchase an additional 2,083,334 shares until August 14, 2021 . As at the date of this news release, PLAN has received $116,000 and will receive another $284,000 if the remaining shares are purchased under the option agreements.

Keep reading... Show less

First Products to Hit California Shelves in Q2 2021

 4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that its fully funded state of the art 185,000 square foot production facility in Commerce, California is nearing completion and will be ready to serve the $3b California cannabis market in Q2 2021. The project is on target to be completed in April 2021 with the Company planning for the first of its full line of edibles, tinctures and vape products to be on California retail shelves by May.

Keep reading... Show less